CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-Operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) [gefitinib] in Upper Aerodigestive Tract Carcinomas

Trial Profile

CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-Operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) [gefitinib] in Upper Aerodigestive Tract Carcinomas

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms CARISSA; GORTEC GETTEC CARISSA
  • Most Recent Events

    • 14 Nov 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 14 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Researchers in this trial are aiming to identify a subgroup of patients with head and neck cancer who are sensitive to gefitinib. According to an abstract presented at ASCO 2010, samples from 82 patients have been collected towards this end, to date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top